507
Participants
Start Date
April 30, 2016
Primary Completion Date
April 30, 2019
Study Completion Date
April 30, 2019
Engensis (VM202)
gene therapy
placebo
Columbia University Medical Center Department of Neurology, New York
Martin Foot and Ankle, York
EVMS (Eastern Virginia Medical School), Norfolk
Raleigh Neurology Associates, P.A., Raleigh
UF Health College of Med, Jacksonville, Jacksonville
University of Florida McKnight Brain Institute, Gainesville
Compass Research, LLC, Orlando
Clinical Research of West Florida, Tampa
Innovative Research of West Florida, Clearwater
University of Minnesota, Minneapolis
Northwestern University, Chicago
University of Kansas Medical Center Research Institute, Kansas City
Clinical Trials, Inc., Little Rock
Nerve and Muscle Center of Texas, Houston
University of Utah -Neurology, Salt Lake City
Arizona Research Center, Phoenix
Neurological Research Institute, Santa Monica
Center for Clinical Research, San Francisco
Diablo Clinical Research, Inc., Walnut Creek
Richard S. Cherlin, MD, Los Gatos
Northern California Research, Sacramento
Rainier Clinical Research Center, Inc., Renton
Western Washington Medical Group, Everett
Associated Neurologists of Southern Connecticut, PC, Fairfield
The Brigham and Women's Hospital, Boston
Helixmith Co., Ltd.
INDUSTRY